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Abstract
Background: The cytokine-induced anti-apoptotic molecule (CIAPIN1) had been found to be a differentially-
expressed gene involved in a variety of cancers, and it was also considered as a candidate tumour suppressor gene
in gastric cancer, renal cancer and liver cancer. However, studies on the role of CIAPIN1 in colorectal cancer were
still unavailable. The aim of this study was to determine the prognostic impact of CIAPIN1 in 273 colorectal cancer
(CRC) samples and to investigate the CIAPIN1 expression in CRC cell lines after inducing differentiation.
Methods: Immunohistochemical analysis was performed to detect the expression of CIAPIN1 in CRC samples from
273 patients. The relationship between CIAPIN1 expression and patients’ characteristics (gender, age, location of
cancer, UICC stage, local recurrence and tumour grade factors) was evaluated. In addition, these patients were
followed up for five consecutive years to investigate the relationship between CIAPIN1 expression and the
prognosis of CRC. We induced the differentiation of the CRC cell lines HT29 and SW480, in order to detect the
expression of CIAPIN1 in the process of CRC cells differentiation.
Results: Results indicated that CIAPIN1 was mainly expressed in the cytoplasm and nucleus, and that its expression
level in cancer samples was significantly lower than in normal tissues. The Wilcoxon-Mann-Whitney test showed a
significant difference in the differential expression of CIAPIN1 in patients with different T and UICC stages, and
tumour grade (P = 0.0393, 0.0297 and 0.0397, respectively). The Kaplan-Meier survival analysis demonstrated that
the survival time of CRC patients with high expression of CIAPIN1 was longer than those with low expression
during the 5-year follow up period (P = 0.0002). COX regression analysis indicated that low expression of CIAPIN1,
cancer stage of > pT1, distant organ metastasis (pM1), regional lymph node metastasis (> pN1) and local recurrence
(yes) were independent, poor prognostic factors of CRC (P = 0.012, P = 0.032, P< 0.001, P< 0.001, P< 0.001
respectively). Both Western blotting and RT-PCR showed that CIAPIN1 expression was increased with the degree of
differentiation of HT29 and SW480 cells.
Conclusions: CIAPIN1 played an important role in the differentiation of CRC cells, and the differential expression of
CIAPIN1 in CRC was closely related to prognosis.
Background
Colorectal cancer (CRC) is one of the three leading causes
of cancer-related death among men and women in the
world, and there are approximately 1,020,000 new cases
and 530,000 deaths worldwide per year [1,2]. It is one of
the most common malignant tumours in China. During
the past decades, the incidence of CRC had been
increasing, and some reports indicated that the mortality
of CRC had been increasing as a result of early metastases
[3]. Despite curative surgical resection of the primary
tumour, 40% to 50% of the patients ultimately die of
metastases [4-6]. Tumour growth and metastasis result
from a complex cascade of biological processes. Therefore,
understanding key factors in these processes is crucial to
the design of new treatment modalities. Although many
molecular markers, including carcinoembryonic antigen
(CEA), have been exploited for detecting CRC, these lack
sensitivity and specificity for evaluating the prognosis of
CRC patients [7-10]. Thus, there is an urgent demand for
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diagnostic and prognostic markers for CRC.
Cytokine-induced anti-apoptosis molecule 1 (CIA-
PIN1) originally named anamorsin or V62, was a newly
identified apoptosis-related molecule that had been
proved to be a mediator of the RAS signalling pathway.
It also played a vital role in foetal liver haematopoiesis
[11,12]. Previous studies by our group confirmed that
CIAPIN1 was widely expressed in adult and foetal tis-
sues, but that the expression levels varied in different
tissues. There were high expressions of CIAPIN1 in
well-differentiated or metabolically active tissues [12,13].
We speculated that CIAPIN1 might play important phy-
siological functions in the human body.
Our laboratory also indicated a direct correlation
between the loss of CIAPIN1 and the proliferation of
tumours in human digestive cancer [14,15]. Immunohisto-
chemical studies had shown that there was low expression
of CIAPIN1 in gastric cancer, but the expression in the
corresponding adjacent tissues and normal tissues was
high. Up-regulation of CIAPIN1 expression in gastric can-
cer cell lines demonstrated that CIAPIN1 might be
involved in the regulation of gastric cancer cell prolifera-
t i o na n da p o p t o s i s .T h e s ef i n d i n g ss u g g e s t e dt h a tt h e
expression of CIAPIN1 was negatively related to cell pro-
liferation; in particular, the proliferation of cancer cells.
In this study, the expression level of CIAPIN1 was
detected in 273 samples from patients with CRC. The
relationship between expression of CIAPIN1 and survi-
val time during the 5-year follow-up period was evalu-
ated. In addition, we investigated the expression of
CIAPIN1 after inducing differentiation in colorectal can-
cer cell lines. Our study provides explicit evidence of the
regulation of CIAPIN1 in CRC cells and indicates that
CIAPIN1 may be a prognostic marker in CRC.
Methods
Patients and collection of samples
A total of 273 patients with primary CRC, who under-
went surgery at the Department of Anorectal Surgery at
Tianjin Union Medicine Centre, were recruited for this
study from 2000 to 2003. The mean age was 58 years
(range: 23~82 years) with 136 women and 137 men. Can-
cer tissues, along with normal tissues that were at least
5 cm away from the cancer, were obtained from the
patients. Western blot analysis was performed on fresh
samples from 40 CRC patients. All 273 patients’ survival
information of 60 month postoperative follow-up was
received by telephone and mail. The median follow-up
period was 39.7 months (range: 10~65 months). Patients’
characteristics, such as gender, age, location of the
tumour, UICC stage, local recurrence and tumour stage
factors, were obtained from the medical records. Patient
characteristics are summarised in Table 1. All resection
samples were confirmed to be CRC by clinical pathology.
All the patients were staged based on the UICC staging
system. Of the 273 patients, 24 (8.8%) had T1-stage, 33
(12.1%) had T2-stage, 182 (66.7%) had T3-stage, and 34
(12.4%) had T4-stage CRC. Tissues were fixed in 10% for-
maldehyde, embedded in paraffin, cut into 4- μms e c -
tions, and mounted on slides. All patients gave informed
consent to use excess pathological specimens for research
purposes. The protocols used in the study were approved
Table 1 Correlation between clinicopathological
characteristics and CIAPIN1 expression
CIAPIN1
(-/+)
CIAPIN1
(++)
CIAPIN1
(+++)
P
Age 0.4756
≤75 111(62.7) 41(23.2) 25(14.1)
>75 54(56.3) 31(32.2) 11(11.5)
Gender 0.1939
Male 77(56.2) 41(22.9) 19(13.9)
Female 88(64.7) 31(22.8) 17(12.5)
Location 0.5037
Right 44(66.7) 14(21.2) 8(12.1)
Left 25(50.0) 19(38.0) 6(12.0)
Rectum 54(60.7) 23(25.8) 12(13.5)
Sigmoid 42(61.8) 16(23.5) 10(14.7)
Local
recurrence
0.1914
Yes 53(65.4) 21(25.9) 7(8.6)
No 112(60.4) 51(26.4) 29(13.2)
pT 0.0393
pT1 8(33.3) 10(41.7) 6(25.0)
pT2 20(60.6) 9(27.3) 4(12.1)
pT3 114(62.6) 48(24.4) 20(11.0)
pT4 23(67.7) 5(14.7) 6(17.6)
pN 0.2832
pN0 85(57.4) 42(28.4) 21(14.2)
pN1 80(64.0) 30(24.0) 15(12.0)
pM 0.9502
pM0 135(60.0) 63(28.0) 27(12.0)
pM1 30(62.5) 9(18.8) 9(18.8)
L stage 0.1689
L0 77(56.6) 38(27.9) 21(15.4)
L1 88(64.2) 34(24.8) 15(10.9)
V stage 0.9732
V0 63(60.0) 27(25.7) 15(14.3)
V1 57(61.3) 24(25.8) 12(12.9)
V2 45(60.0) 21(28.0) 9(12.0)
UICC 0.0297
I+II 71(53.8) 40(30.3) 21(15.9)
III+IV 94(66.7) 32(22.7) 15(10.6)
Tumour grade 0.0397
Well 51(75.0) 8(11.8) 9(13.2)
Moderately 92(54.4) 53(31.4) 24(14.2)
Poorly 22(61.1) 11(30.6) 3(8.3)
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tee. The use of human tissues in this study was approved
by the institutional review board of the Fourth Military
Medical University and was done in accordance with
international guidelines. Of the 273 patients, 23 (8.4%,
some CRC patients with stage IV of UICC) received
neoadjuvant chemotherapy, 242 (88.6%, CRC patients
w i t hs t a g eI I B ,I I C ,I I Ia n dI Vo fU I C C )u n d e r w e n ts u r -
gery alone and received subsequent chemotherapy, and
31 (11.4%, CRC patients with stage I and IIA of UICC)
only received surgical treatment.
Immunohistochemical staining [12,13]
The cancer and normal tissues from 273 patients were
embedded in paraffin and cut into sections for immuno-
histochemical analysis. Immunohistochemistry was per-
formed using the Histostain-Plus SP kit, which offers
superior sensitivity. Briefly, the sections were deparaffi-
nised with xylene and rehydrated through gradient ethanol
immersion. Endogenous peroxidase activity was quenched
by 0.3% (v/v) hydrogen peroxide in methanol for 20 min,
followed by three 5-min washes with PBS. The sections
were then blocked with 10% (v/v) normal goat serum in
PBS for 1 hr, followed by overnight incubation at 4°C with
the anti-CIAPIN1 antibody diluted (1:200, initial concen-
tration 1.8 mg/ml; Mouse anti-CIAPIN1 MAb was devel-
oped by our laboratory) [12,13] in PBS containing 3%
(wt/vol) BSA. A negative control was performed by repla-
cing the primary antibody with pre-immune mouse
serum. After three 5 min washes with PBS containing
0.02% (v/v) Tween-20 (PBST), the sections were treated
with biotinylated goat anti-mouse antibody for 20 min at
room temperature, followed by three additional 5 min
washes with PBST. Then, the specimens were incubated
with streptavidin-horseradish peroxidase for 20 min at
room temperature followed by repeated washes, as
described above. Reaction product was visualised with
DAB at room temperature for 5 min. Sections were coun-
terstained with haematoxylin for 30 sec and rinsed with
tap water, immediately dehydrated by sequential immer-
sion in gradient ethanol and xylene and were then
mounted with Permount onto coverslips. Images were
obtained under a light microscope (Olympus BX51;
Olympus, Japan) equipped with a DP70 digital camera.
Immunohistochemical analysis
S e c t i o n sw i t h o u tt h ep r i m a r ya n t i b o d yw e r eu s e da s
negative controls. Clear cell renal cell carcinoma samples
that previously showed immunoreactivity to the CIA-
PIN1 antibody were used as positive controls to confirm
CIAPIN1expression. The slides were evaluated indepen-
dently by two pathologists who were blinded to the study
[14-16]. Any disagreement was resolved by consensus
after joint review. Expression of CIAPIN1 was evaluated
as the percentage of positive cells and staining intensity
as previously described. The percentage of positive cells
was evaluated quantitatively and scored as 0 for staining
of ≤1% of total cells counted, 1 for staining of 2~25%,
2 for staining of 26~50%, 3 for staining of 51~75%, and 4
for staining of >75% of the cells examined. Intensity was
graded as follows: 0, no signal; 1, weak; 2, moderate; and
3, strong staining. A total ‘staining score’ of 0~12 was cal-
culated and graded as negative (-, score 0~1), weak (+,
score 2~4), moderate (++, score 5~8), or strong (+++,
score 9~12) [16,17].
Statistical analysis
The relationship between CIAPIN1 expression levels
and clinicopathological factors was analysed using the
Wilcoxon-Mann-Whitney test. The overall survival time
of CRC patients was defined as the time from the sur-
gery to death due to cancer. The Kaplan-Meier method
was used to determine the cumulative probability of sur-
vival, and data were analysed with the log-rank test.
Univariate and multivariate statistical analyses were
done using the Cox regression model to investigate the
effects of patients’ characteristics (CIAPIN1 status, gen-
der, age, location, extent of primary tumour, nodal sta-
tus, metastasis and histological grade) on overall
survival. A score was assigned to each variable for the
Cox regression analysis [17,18]. A value of P <0 . 0 5w a s
considered statistically significant.
Additionally, receiver operator characteristic (ROC)
curves were constructed for expression of CIAPIN1 as
ap r e d i c t o rf o r‘patient death’ and ‘cancer local recur-
rence’. The ROC curve determines how effective a pre-
dicted risk value is at discriminating a bivariable
outcome (in this case ‘death’ or ‘no death’,o r‘local
recurrence’ or ‘non- local recurrence’)b yc o n s t r u c t i n g
a graph with sensitivity on the Y-axis and one specifi-
city on the X-axis. It depicts the inverse relationship
between sensitivity and specificity.
Western blotting
Equal amounts of total proteins were loaded on 12%
SDS PAGE and electroblotted onto a nitrocellulose
membrane. Non-specific binding was blocked with 5%
non-fat milk in PBS for 1 hr at room temperature.
Then, the membrane was incubated with anti-CIAPIN1
MAb (1:400) overnight at 4°C, rinsed with TBST three
times and then incubated with HRP-labelled goat anti-
mouse IgG for 1 hr. After three washes with TBST, the
bands were developed with the enhanced chemilumines-
cence reagent for 5 min [14].
Reverse transcription-PCR analysis
Total RNA was extracted using TRIzol reagent (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s
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reverse transcription. The polymerase chain reaction
(PCR) primers used were as follows: for CIAPIN1, 5′-
CGG AAT TCATGG CAG ATT TTG GGA TCT C-3′
(forward), 5′-GGT CGA CCT AGG CAT CAA GAT
TGC TAT C-3′ (reverse) and for b-actin, 5′-ATG
ATATCG CCG CGC TCG TC-3′ (forward), 5′-CGC
TCG GTG AGG ATC TTC A-3′(reverse). PCR products
were separated on a 1% agarose gel, visualised and
photographed under ultraviolet light [14].
Cell culture
The human CRC cell lines LoVo, CoLo205, HCT116,
HT-29, SW620, and SW480 were obtained from the
American Type Culture Collection (Rockville, MD,
USA) and maintained as recommended. Cells were cul-
tured in DMEM with 2 mM l-glutamine and Earle’s
balanced salt solution (BSS) adjusted to contain 1.5 g/L
sodium bicarbonate, 0.1 mM nonessential amino acids,
and 1.0 mM sodium pyruvate. All culture fluid was sup-
plemented with 10% FCS. All cells were cultured with
5% CO2 at 37°C in a humidified chamber [17,18].
Induction of cell differentiation [18,19]
The human colon carcinoma cell lines HT29 and
SW480 were cultured in L-15 medium (Sigma-Aldrich).
The media contained 10% foetal bovine serum (Atlanta
Biologicals), and cells were cultured at 37°C in 5% CO2.
Differentiation was induced by treatment with 2 mM
sodium butyrate (Sigma Chemical) for 6 d, and cells
were harvested each day from the beginning of treat-
ment to the sixth day. The differentiation stage was
assessed by transmission electron microscopy (TEM; for
changes in cell structure and architecture) and degree of
alkaline phosphatase (AP) activity. After removal of the
culture medium, the attached cells were scraped into
ice-cold PBS, centrifuged at 4000 × g, resuspended in
PBS, and sonicated with an ultrasonic cell disrupter.
Cellular debris was pelleted by centrifugation, and
supernatants were transferred to new tubes and stored
at -70°C until measurement. AP activity was measured
according to the manufacturer’s instructions using
p-nitro-phenylphosphate as the substrate (Merck,
Darmstadt, Germany) and calculated in units per milli-
gram protein (U/mg prot). Protein content was deter-
mined using a BCA™ Protein Assay Kit.
Results
Expression of CIAPIN 1 in Human Colorectal Cancer and
Its Correlation With Prognosis
The expression of CIAPIN1 by immunoreactivity with
the specific MAb was generally localised in both the
cytoplasm and the nucleus of colonic epithelial tissues
Fig. 1[A(a-e)]. CIAPIN1-positive expression in CRC was
47.25% (129/273), significantly lower than 79.85% (218/
273) in the unaffected tissue adjacent to the tumour
(P< 0.01). CIAPIN1 protein expression in CRC was
significantly decreased compared with that in normal
colonic epithelial tissues. In addition, its expression level
decreased from well-differentiated to poorly differen-
tiated tumours Fig. 1[A(c-e)]. However, there was no
significant difference in the expression level of CIAPIN1
protein between normal and gland hyperplasia of colo-
nic mucous membrane tissues Fig. 1[A(a-b)]. As shown
in Fig. 1A and Table 1, 273 CRC patients were subdi-
vided into the following three subgroups based on the
expression levels of CIAPIN1, 165 with none to weak
expression (60.4%; -/+), 72 with moderate to locally
strong expression (26.4%; ++), and 36 with strong
expression (13.2%; +++).
The correlation between expression level of CIAPIN1
and patients’ characteristics, such as gender, age, loca-
tion of cancer, UICC stage, local recurrence and tumour
stage factors was investigated. CIAPIN1 protein expres-
sion correlated with having a primary tumour (pT),
tumour stage (UICC), and histological grade (Table 1;
P = 0.0393, 0.0297, and 0.0397, respectively). No corre-
lation was observed between CIAPIN1 expression and
age, gender, location, local recurrence, L stage, V stage,
pN and pM. The overall survival analysis using the
Kaplan-Meyer method revealed that the prognosis of
CRC patients with high or moderate CIAPIN1 expres-
sion was significantly better than those with no or weak
CIAPIN1 expression, and high expression was better
than moderate expression (Fig. 1(B); P = 0.0002).
The ROC curve for non-local recurrence within
5 years (Fig. 1(C)) showed that the score 7 of CIAPIN1
expression level provided maximal sensitivity (0.63) and
specificity (0.74). Similarly, the curve for survival after
5 years (Fig. 1(C)) showed that the score 6 of CIAPIN1
expression level provided a maximal sensitivity (0.61)
and specificity (0.73). The area under the curve for non-
local recurrence was 0.74 and for survival was 0.71. This
shows that the score of CIAPIN1 expression level did
predict non-local recurrence and survival.
Both univariate and multivariate analyses showed that
primary tumour (pT3/pT4), regional lymph node metas-
tasis (pN1), distant tumour metastasis (pM1), local
recurrence (yes) and low-expression CIAPIN1 (-/+)
were independent, poor prognostic factors of CRC
(Table 2 and Table 3); However, age (> 75 years), gen-
der (male), location (rectum or sigmoid), adjuvant ther-
apy (yes) and tumour grade (> G2) were not related to
the prognosis of CRC (Table 2 and Table 3).
Analysis of CIAPIN1 Expression by Western Blot
To accurately quantify CIAPIN1 expression level
changes in colorectal carcinomas, we performed
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Page 4 of 10Figure 1 (A) Immunohistochemical staining of CIAPIN1 in CRC tissues. (a) Normal colonic epithelium, strong staining (+++) was observed in
the normal colon epithelial tissues, mainly in the epithelial cells, and no evidence of expression of CIAPIN1 was noted in cells of the germinal
layer (×200). (b) Gland hyperplasia of colonic mucous membrane, strong staining (+++) of CIAPIN1 was observed in dysplasia colonic epithelial
tissues, there was no significant difference in the expression level of CIAPIN1 protein between normal and dysplasia colon tissues (×200). (c)
Well-differentiated adenocarcinoma of colon, intermediate staining (++) of CIAPIN1 in CRC tissues with high differentiation mainly in the
epithelial tissues (×200). (d) Moderately differentiated adenocarcinoma of colon, weak staining (+) of CIAPIN1 in CRC tissues with moderately
differentiation, mainly in the epithelial tissues (×200). (e) Poorly differentiated adenocarcinoma of colon, negative staining (-) of CIAPIN1 in CRC
tissues with poorly differentiation (×200). (f) Negative control slides using anti-His as the primary antibody. (B) Overall survival of patients
determined by the immunoreactivity of CIAPIN1. Overall survival analysis using the Kaplan-Meyer method revealed that CRC patients with
relatively high expression of CIAPIN1 had a more favourable prognosis compared to those with low expression (P = 0.0002). (C) Receiver
operating characteristic (ROC) curve for non-local recurrence (circles) within 5 years and survival (triangles) after 5 years.
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Page 5 of 10Western blot analysis in 40 CRC tissues and matched
normal tissues. Among the 40 clinical specimens, as
expected, 28 (70.0%) samples of CRC tissues showed
lower expression than that in adjacent normal tissues; 7
(18.5%) samples of CRC tissues showed higher expres-
sion than that in adjacent normal tissues; and 5 (11.5%)
samples of CRC tissues showed no expression. Based on
these results, we confirmed that CIAPIN1 protein
expression was lower in carcinomas tissues compared
with adjacent normal tissues (Fig. 2(A)). We subse-
quently investigated whether the expression of CIAPIN1
correlated with the differentiation status and UICC
stage as shown by immunohistochemistry. CIAPIN1ex-
pression was found to be increased in well-differentiated
tumours (Fig. 2(B)). Furthermore, CIAPIN1 expression
decreased gradually with increasing stage (Fig. 2(C)).
This was consistent with the results of the immunohis-
tochemistry experiments.
CIAPIN1 expression increased in colon carcinoma cells
after inducing differentiation
CIAPIN1 gene and protein expression levels were tested
in the human CRC cell lines LoVo, CoLo205, HCT116,
HT-29, SW620, and SW480. As shown in Fig. 3A, CIA-
PIN1 expression was detected in all CRC cell lines. To
investigate the expression of CIAPIN1 during CRC cell
differentiation, in vitro studies with HT-29 and SW480
CRC cell lines were performed. Cells were treated with 2
mM sodium butyrate to induce differentiation. Following
incubation, the differentiation status was confirmed by
TEM examination of the presence of regular brush bor-
ders and tight junctions, which are structural markers of
differentiation (Fig. 3B). In addition, butyrate-induced
differentiation was measured by alkaline phosphatase
(AP) activity. AP activity increased significantly in HT-29
and SW480 cells after 48 h of incubation (Fig. 3C). Both
protein and mRNA expression levels of CIAPIN1 were
measured in HT29 and SW480 cell lines at the indicated
time points after butyrate treatment. Prolonged incuba-
tion with butyrate resulted in a time-dependent induction
of CIAPIN1expression (Fig. 3D).
Disscussion
CIAPIN1 was a recently reported anti-apoptotic mole-
cule, but its biological function was far from being fully
understood. In the previous study [12], we observed the
distribution of the CIAPIN1 in a variety of cultured cell
lines, including mouse fibroblast cell line NIH3T3,
human tumor cell lines and immortalized cell lines by
using immunofluorescence staining, immunohistochem-
istry and EGFP-CIAPIN1 fusion protein. It was shown
that CIAPIN1 was distributed both in the cytoplasm,
but it was more concentrated in the nuclei. To further
confirm the above results, Western blot was used to
detect the distribution of CIAPIN1 in the sub-cellular
Table 2 Cox univariate analysis
Variables Wald chi-square df P
Age 2.587 1 0.108
Gender 2.798 1 0.094
Location 0.462 1 0.497
Neoadjuvant therapy 2.474 1 0.116
Local recurrence 5.549 1 0.018
pT 10.861 1 0.001
pN 7.704 1 0.006
pM 14.783 1 < 0.001
L stage 1.431 1 0.232
V stage 2.128 1 0.145
Tumour grade 3.293 1 0.070
CIAPIN1 6.468 1 0.011
Variables (Location, pT, Tumour grade, V satge, CIAPIN1) in table 2 were
adjusted for binary variables.
Table 3 Cox multivariate analysis
Variables Risk ratio (95% confidence interval) P
Age (>75 y) 1.100 (0.714-1.694) 0.665
Gender (male) 1.410 (0.712-2.794) 0.324
Location (Rectum or Sigmoid) 0.753 (0.512-1.106) 0.149
Neoadjuvant therapy (Yes) 0.661 (0.329-1.328) 0.245
Local recurrence (Yes) 2.181 (1.382-3.441) < 0.001
Primary tumour (pT3 or pT4) 1.697 (1.060-2.718) 0.028
Regional lymph node metastasis (pN1) 2.307 (1.434-3.710) 0.001
Distant metastasis (pM1) 2.504 (1.555-4.030) < 0.001
L stage (L1) 1.199 (0.845-1.700) 0.309
V stage (V1 or V2) 0.811 (0.573-1.148) 0.237
Tumour grade (> G2) 0.723 (0.447-1.170) 0.186
CIAPIN1 (++ or +++) 0.263 (0.114-0.608) 0.002
CIAPIN1: Cytokine-induced anti-apoptotic molecule.
Values are mean ± SD, n = 3. CIAPIN1: Cytokine-induced anti-apoptotic molecule.
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Page 6 of 10Figure 2 Detection of CIAPIN1 expression in freshly obtained CRC tissues Western blot analysis. (A) CIAPIN1 expression level in cancerous
and adjacent normal tissues from the same patients. (B) CIAPIN1 expression level in poorly, moderately, and well-differentiated cancer tissues. (C)
CIAPIN1 expression in cancer tissues with different TNM stages. b-Actin staining was used as a control for equal protein loading.
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Page 7 of 10Figure 3 (A) RT-PCR and western blotting results showing CIAPIN1 transcripts and protein in CRC cell lines. b- A c t i nw a su s e da sa n
internal control. (B) Electron microscopy of colon cancer cells during the process of induced differentiation. (a) Undifferentiated colon cells; (b-f)
Changes in ultra-microstructure during colon cell differentiation. There were special conformations such as cryptate structures, tight junctions
and macula adherens between cells, as well as polarisation of microvilli in differentiated HT29 and SW480 cells. (C) AP level during induced cell
differentiation in two different colon cancer cell lines. AP levels in HT29 and SW480 were measured from the 1st to the 5th day during the
induced differentiation process and compared with untreated cells (day 0). (D) RT-PCR and Western blotting results showing CIAPIN1 transcripts
and protein changes during HT29 and SW480 cell line differentiation from the 1st to 5th day of induced differentiation compared with
untreated cells (day 0). b-Actin was used as an internal control.
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Page 8 of 10components by separating sub-cellular component of
HepG2. The results were consistence with immunologi-
cal method. It would indicate that CIAPIN1 might be
involved in a cytoplasm-nucleus-nucleolus translocation
process in the cells, and nucleoli might be the final area
o ro n eo ft h ef i n a la r e a sw h e r eC I A P I N 1m a yp l a yi t s
biological function. Another possibility was that nucleoli
might be an important storage place of CIAPIN1.
Our group found that CIAPIN1 protein existed in
many organs of mice at different time points after birth.
From 1 to 7 days after birth, the expression of CIAPIN1
gradually strengthened in heart, brain, liver, kidney and
skeletal muscle [12]. The expression of CIAPIN1 could
also be detected in many organs of the 5 month old
human embryo. The expression level of CIAPIN1 in
adult organs of endodermal and ectodermal origin was
lower than that in 5 month old human embryo. But the
result in the organs derived from mesoderm was the
opposite [13]. These findings were suggested that CIA-
PIN1 was a new gene which was closely related to
differentiation.
We previously confirmed that CIAPIN1 expression in
gastric cancer, liver cancer and clear cell renal cell carci-
noma (CCRCC) was down-regulated compared to their
adjacent normal tissue counterparts. Furthermore, stable
transfection of CIAPIN1 siRNA may contribute to carci-
nogenesis by accelerating cell proliferation and promot-
ing cell-cycle progression in vitro and in vivo in the two
tumour types [17,19-21]. Our group also demonstrated
that CIAPIN1 inhibited gastric cancer and CCRCC cell
proliferation, as well as cell-cycle progression by down-
regulating CyclinD1 and up-regulating P27. CIAPIN1
siRNA could also significantly down-regulate the expres-
sion of Bcl-2, and up-regulate the expression of Bax but
not that of PTEN in gastric cancer cells. These observa-
tions suggested that the siRNA constructs of CIAPIN1
could effectively down-regulate the expression of CIA-
PIN1 and reverse the multidrug resistant phenotype of
gastric cancer cells.
In the present study, we first investigated the expres-
sion of CIAPIN1 in human CRC tissues and cell lines
with the aim of investigating the molecular mechanisms
of CRC tumorigenesis, and ultimately, to find a new
molecular marker of the early diagnosis and prognosis
of CRC. Our results showed that the CIAPIN1 protein
was expressed in the nucleus and cytoplasm of colorec-
tal glands epithelial cells, and CIAPIN1 expression was
significantly decreased in CRC specimens compared to
their adjacent non-cancerous tissues. The expression
level of CIAPIN1 was closely related to the prognosis of
patients with CRC. The overall survival of patients with
high or moderate CIAPIN1 expression was significantly
better than those with none or weak CIAPIN1 expres-
sion, and low expression levels of CIAPIN1 associated
with the tumour stage, lymph node metastasis, distant
organ metastasis and local recurrence were independent,
poor prognostic factors of CRC. These data suggested
that CIAPIN1 was associated with CRC, and the
decreased expression of CIAPIN1 was correlated with a
worse outcome of CRC patients. CIAPIN1 could be con-
sidered as a potentially valuable prognostic indicator in
patients with CRC. This information might be useful to
clinicians in providing individualized therapy for CRC
patients with optimal benefit.
In this study, we also observed CIAPIN1 expression, at
both the mRNA and protein levels, in the human CRC
cell lines LoVo, CoLo205, HCT116, HT-29, SW620, and
SW480. Our results suggest that CIAPIN1 gene expres-
sion might be different in CRC and normal colorectal
tissue, and CIAPIN1 might be involved in colorectal car-
cinogenesis and development, as well as functioning as a
tumor suppressor gene in CRC. To determine whether
CIAPIN1 could be involved in the differentiation of
CRC cells, we induced differentiation of HT29 and
SW480 cells. We found that both the CIAPIN1 protein
and mRNA levels increased gradually over time and
with differentiation status. The changes in CIAPIN1
expression during the differentiation of CRC cells may
provide an important clue to understand its function in
CRC cell differentiation. This finding is consistent with
Hao’s data [12,13], but it still does not explain the func-
tion of CIAPIN1. More studies are needed to prove the
regulatory mechanisms and signaling pathways of this
gene in cell differentiation.
Previous study of our group had shown that CIAPIN1
was involved in the regulation of multidrug resistance
(MDR) of gastric cancer cells [14,15,22]. We also found
that the expression of CIAPIN1 was higher in the cells
of gastric cancer SGC7901/VCR than in SGC7901 cells.
In addition, it was demonstrated that CIAPIN1 could
increase the expression of P-gp and the relative ratio of
Bcl-2/Bax in SGC7901/VCR cells. CIAPIN1 siRNA
could reverse the phenotype of MDR in SGC7901/VCR
cells. These results suggested that inhibition of exocyto-
sis of the anticancer drugs and resistance to chemother-
apy-induced apoptosis might be the important
mechanism for CIAPIN1 to mediate the MDR of gastric
cancer cells. In the present study, we could not get
direct evidence of CIAPIN1 regulating the MDR of CRC
cells. But, we did find that CIAPIN1 played an impor-
tant role in regulating the tumorigenesis and cell differ-
entiation of CRC. There was no significant survival
benefit for CRC patients from neoadjuvant chemother-
apy. However, there was significant survival benefit from
high expression of CIAPIN1.
Taken together, our results revealed that CIAPIN1
was differentially expressed in normal adjacent tissues
and cancer tissues from the same CRC patient and that
Shi et al. BMC Cancer 2010, 10:477
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Page 9 of 10CIAPIN1 expression was closely related to the tumour
state, local recurrence and UICC stage. Low expression
level of CIAPIN1 might act as an independent, poor
prognostic factor of CRC. These data suggested that
CIAPIN1 might have an important role in the develop-
ment of colorectal cancer. Although the regulatory
mechanism of CIAPIN1 in CRC was still unclear, our
studies had provided evidence that CIAPIN1 expression
correlated with the differentiation level and prognosis of
CRC, suggesting it was an important role in tumour
biology.
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